As of 10:06am ET
| -0.04 / -4.49%|
The 2 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 4.25, with a high estimate of 5.00 and a low estimate of 3.50. The median estimate represents a +400.00% increase from the last price of 0.85.
The current consensus among 3 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.